Sanofi SA (SASY.PA) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Finlabo SIM Spa
$10.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Regeneron and Sanofi announce positive results from phase 2b study of dupilumab in patients with moderate-to-severe atopic dermatitis


Wednesday, 9 Jul 2014 05:00pm EDT 

Regeneron Pharmaceuticals Inc:Says that the company and Sanofi announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline compared to placebo.Dupilumab is an investigational monoclonal antibody that blocks signaling of IL-4 and IL-13, two cytokines that play a key role in the pathogenesis of moderate-to-severe atopic dermatitis. 

Company Quote

72.82
2.4 +3.41%
11:39am EDT